Log In
Print
BCIQ
Print
Print this Print this
 

Factor VIIa-CTP

  Manage Alerts
Collapse Summary General Information
Company Opko Health Inc.
DescriptionLong-acting formulation of recombinant Factor VIIa developed using carboxyl terminal peptide (CTP) technology
Molecular Target Factor VIIa
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPreclinical
Standard IndicationHemophilia
Indication DetailsOn-demand and prophylactic treatment of hemophilia; Prophylactic treatment of hemophilia; Treat bleeding episodes in patients with hemophila A or B with inhibitors to Factor VIII or Factor IX; Treat hemophilia
Regulatory Designation

U.S. - Orphan Drug (Treat bleeding episodes in patients with hemophila A or B with inhibitors to Factor VIII or Factor IX)

Partner


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today